Profile photo

Nuclear Medicine and Theranostics With Jeremie Calais, MD, MSc

Oncology / Hematology

Dr. Calais is a nuclear medicine physician who specializes in cancer imaging and theranostics. He is an associate professor at the David Geffen School of Medicine, director of the UCLA Theranostics Program, and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division. He conducts investigator-initiated and industry-sponsored clinical trials of targeted molecular imaging and radio nuclide therapy.

SUO 2024 Highlights on Prostate Cancer Research

Dear readers,

In my final newsletter about prostate cancer at the SUO 25th Annual Meeting, I wanted to highlight a few studies that caught my eye.

First, I included a study on U.S. patients with mCRPC treated with olaparib presented by Dr. Daniel George. He discussed real-world and clinical outcomes in this patient population. Dr. Ganesh Palapattu also presented on the biology of cancer metastases. He delved into the history, lexicology, and modern interpretations and research.

My final post discusses the phase 1B/2 study of combination 177Lu girentuximab + cabozantinib and nivolumab. The treatment was studied in treatment-naive patients with advanced clear cell RCC. Check it out!

Best regards,
Jeremie Calais, MD, PhD

Articles
  • Mashup Score: 42
    SUO 2024: Biology of Cancer Metastases - 3 month(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Biology of cancer metastases. Presentation by @gpalapa2 @UMich. #SUO24 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/0wb6rSXWze @UroOnc https://t.co/5bp9NT2RW5